The Experts below are selected from a list of 72 Experts worldwide ranked by ideXlab platform
Dairong Chen - One of the best experts on this subject based on the ideXlab platform.
-
Ultrasensitive electrochemiCAl immunosensor for CA 15-3 using thionine-nanoporous gold–graphene as a platform and horseradish peroxidase-enCApsulated liposomes as signal amplifiCAtion
The Analyst, 2012Co-Authors: Xiuling Jiao, Dairong ChenAbstract:This paper describes a novel electrochemiCAl immunosensor using a nanoporous gold (NPG)/graphene (GN) hybrid platform combined with horseradish peroxidase (HRP)-enCApsulated liposomes as labels for the sensitive detection of CAncer Antigen 15-3 (CA 15-3). The electrochemiCAl detection was based on the released HRP from HRP-enCApsulated liposomes toward the reduction of H2O2 with the help of the thionine (TH) electron mediator. In the presence of CA 15-3, HRP@liposomes and TH–NPG–GN formed a sandwich-type immunocomplex, and the immunocomplex increased with the increment of the CA 15-3 concentration in the sample. The more CA 15-3 Antigen in the sample there was, the more HRP@liposomes/anti-CA 15-3 in the immunocomplex there were. Thus, the CAtalytic current increased. Under optimized conditions, the linear range of the immunoassay is 2 × 10−5 to 40 U mL−1 with a detection limit of 5 × 10−6 U mL−1 CA 15-3. The CA 15-3 concentrations of the cliniCAl serum specimens assayed by the developed immunoassay showed consistent results in comparison with those obtained by a commercially available electrochemiluminescence assay. This proposed immunoassay system had many desirable merits including sensitivity, accuracy, and minimal instrumentation required. SignifiCAntly, the new protocol may be quite promising, with potentially broad appliCAtions for cliniCAl immunoassays.
-
ultrasensitive electrochemiCAl immunosensor for CA 15 3 using thionine nanoporous gold graphene as a platform and horseradish peroxidase enCApsulated liposomes as signal amplifiCAtion
Analyst, 2012Co-Authors: Xiuling Jiao, Dairong ChenAbstract:This paper describes a novel electrochemiCAl immunosensor using a nanoporous gold (NPG)/graphene (GN) hybrid platform combined with horseradish peroxidase (HRP)-enCApsulated liposomes as labels for the sensitive detection of CAncer Antigen 15-3 (CA 15-3). The electrochemiCAl detection was based on the released HRP from HRP-enCApsulated liposomes toward the reduction of H2O2 with the help of the thionine (TH) electron mediator. In the presence of CA 15-3, HRP@liposomes and TH–NPG–GN formed a sandwich-type immunocomplex, and the immunocomplex increased with the increment of the CA 15-3 concentration in the sample. The more CA 15-3 Antigen in the sample there was, the more HRP@liposomes/anti-CA 15-3 in the immunocomplex there were. Thus, the CAtalytic current increased. Under optimized conditions, the linear range of the immunoassay is 2 × 10−5 to 40 U mL−1 with a detection limit of 5 × 10−6 U mL−1 CA 15-3. The CA 15-3 concentrations of the cliniCAl serum specimens assayed by the developed immunoassay showed consistent results in comparison with those obtained by a commercially available electrochemiluminescence assay. This proposed immunoassay system had many desirable merits including sensitivity, accuracy, and minimal instrumentation required. SignifiCAntly, the new protocol may be quite promising, with potentially broad appliCAtions for cliniCAl immunoassays.
Xiuling Jiao - One of the best experts on this subject based on the ideXlab platform.
-
Ultrasensitive electrochemiCAl immunosensor for CA 15-3 using thionine-nanoporous gold–graphene as a platform and horseradish peroxidase-enCApsulated liposomes as signal amplifiCAtion
The Analyst, 2012Co-Authors: Xiuling Jiao, Dairong ChenAbstract:This paper describes a novel electrochemiCAl immunosensor using a nanoporous gold (NPG)/graphene (GN) hybrid platform combined with horseradish peroxidase (HRP)-enCApsulated liposomes as labels for the sensitive detection of CAncer Antigen 15-3 (CA 15-3). The electrochemiCAl detection was based on the released HRP from HRP-enCApsulated liposomes toward the reduction of H2O2 with the help of the thionine (TH) electron mediator. In the presence of CA 15-3, HRP@liposomes and TH–NPG–GN formed a sandwich-type immunocomplex, and the immunocomplex increased with the increment of the CA 15-3 concentration in the sample. The more CA 15-3 Antigen in the sample there was, the more HRP@liposomes/anti-CA 15-3 in the immunocomplex there were. Thus, the CAtalytic current increased. Under optimized conditions, the linear range of the immunoassay is 2 × 10−5 to 40 U mL−1 with a detection limit of 5 × 10−6 U mL−1 CA 15-3. The CA 15-3 concentrations of the cliniCAl serum specimens assayed by the developed immunoassay showed consistent results in comparison with those obtained by a commercially available electrochemiluminescence assay. This proposed immunoassay system had many desirable merits including sensitivity, accuracy, and minimal instrumentation required. SignifiCAntly, the new protocol may be quite promising, with potentially broad appliCAtions for cliniCAl immunoassays.
-
ultrasensitive electrochemiCAl immunosensor for CA 15 3 using thionine nanoporous gold graphene as a platform and horseradish peroxidase enCApsulated liposomes as signal amplifiCAtion
Analyst, 2012Co-Authors: Xiuling Jiao, Dairong ChenAbstract:This paper describes a novel electrochemiCAl immunosensor using a nanoporous gold (NPG)/graphene (GN) hybrid platform combined with horseradish peroxidase (HRP)-enCApsulated liposomes as labels for the sensitive detection of CAncer Antigen 15-3 (CA 15-3). The electrochemiCAl detection was based on the released HRP from HRP-enCApsulated liposomes toward the reduction of H2O2 with the help of the thionine (TH) electron mediator. In the presence of CA 15-3, HRP@liposomes and TH–NPG–GN formed a sandwich-type immunocomplex, and the immunocomplex increased with the increment of the CA 15-3 concentration in the sample. The more CA 15-3 Antigen in the sample there was, the more HRP@liposomes/anti-CA 15-3 in the immunocomplex there were. Thus, the CAtalytic current increased. Under optimized conditions, the linear range of the immunoassay is 2 × 10−5 to 40 U mL−1 with a detection limit of 5 × 10−6 U mL−1 CA 15-3. The CA 15-3 concentrations of the cliniCAl serum specimens assayed by the developed immunoassay showed consistent results in comparison with those obtained by a commercially available electrochemiluminescence assay. This proposed immunoassay system had many desirable merits including sensitivity, accuracy, and minimal instrumentation required. SignifiCAntly, the new protocol may be quite promising, with potentially broad appliCAtions for cliniCAl immunoassays.
G. Rolka-stempniewicz - One of the best experts on this subject based on the ideXlab platform.
-
Elevation of serum CA 15-3 Antigen: an early indiCAtor of distant metastasis from breast CAncer. Retrospective analysis of 733 CAses
Przeglad lekarski, 2001Co-Authors: J. Wojtacki, G. Rolka-stempniewicz, W J Kruszewski, M Sliwińska, E. Kruszewska, W Hajdukiewicz, Sliwiński W, M Góralczyk, K. Leśniewski-kmakAbstract:UNLABELLED Aim of study was to summarize six-year institutional experience with serial evaluation of circulating CA15-3 Antigen as a method of early detection of breast CAncer relapse. MATERIAL AND METHODS CA15-3 concentrations were assayed immuno-enzymatiCAlly in the sera of 733 women with breast CArcinoma: in 707 CAses marker was analyzed serially (every 4 months during follow-up after completion of radiCAl treatment and when the relapse of breast CAncer was cliniCAlly suspected) and in 26 patients--at diagnosis of locoregional relapse and\or breast CAncer dissemination; 5493 assays of the CA15-3 Antigen were performed in total. The cut-off limit was established at 30 u/ml. Results of CA15-3 tests were analyzed in relation to cliniCAl status of the disease and dominant site of breast CAncer relapse. RESULTS 1) in patients with distant metastases (N = 149), mean serum CA15-3 values and the percentage of positive results were signifiCAntly higher as compared to CAses with locoregional relapse and CArcinoma of the contralateral breast (N = 54; p < 0.0001) and those without cliniCAl evidence of relapse (N = 530; p < 0.0001), in agreement with previous studies; 2) the highest mean values of CA15-3 were observed in patients with liver and multiple metastases, lower in those with bone or lung secondaries, and the lowest when the metastatic involvement of supraclavicular nodes was noticed; 3) the CA15-3 sensitivity rates were higher in patients with liver or bone metastases (91.7% and 91.4%, respectively), as compared to those with multiple (79.5%) and lung (72.4%) secondaries, and the lowest when metastases in supraclavicular nodes (40.0%) or other organs (60.0%) were diagnosed; 4) the comparison of subjects with liver secondaries and those with other sites of breast CAncer dissemination indiCAted statistiCAlly signifiCAnt difference in the mean CA15-3 values (p < 0.0001) and the number of positive results of the test (p < 0.05); 5) the sensitivity rates of CA15-3 Antigen for one, two, three and more skeletal metastases detected by bone scintigraphy were 50%, 100% and 100%, respectively (N = 30); 6) in 84 out of 116 (72.4%) patients with distant metastases, the increased CA15-3 concentration preceded the cliniCAl diagnosis of the relapse with the median lead time 9 months (range: 1-40); 7) the highest positivity rates of the lead time were observed in patients with liver or lung metastases (93.8% and 81.0%, respectively) and the lowest one in those with multiple sites of metastases (43.0%). CONCLUSION The study confirmed the validity of serial CA15-3 assays in the early diagnosis of breast metastatic disease. It is worth to emphasize the high sensitivity of the CA15-3 test in detecting bone metastases (100% in patients with scintigraphiCAlly diagnosed two or more metastatic lesions), but the group of patients was too small to make our observation conclusive. In none of the studies published previously, the beneficial impact of serial CA15-3 assays during follow-up on survival and quality of life in breast CAncer patients was clearly demonstrated. Thus, modifying treatment based solely on increasing marker levels is not recommended.
-
Usefulness of CA 15-3 Antigen determination for evaluation of response to second-line chemotherapy in patients with breast CAncer: preliminary study
Polskie Archiwum Medycyny Wewnetrznej, 1997Co-Authors: J. Wojtacki, A. Dziewulska-bokiniec, G. Rolka-stempniewiczAbstract:The aim of this study was to assess effects of second-line chemotherapy in metastatic breast CAncer via determination of CA 15-3 marker. Analysis included 73 women, in whom distant metastases were diagnosed within 14-72 months (median: 43) after the completion of basic therapy. Average age of patients at primary diagnosis was 50.7 +/- 12.6 years. Dominant sites of metastases were: liver (27 patients) and lungs (24 patients). Serum CA 15-3 was examined immunoenzymatiCAlly at diagnosis of distant metastases and then after 2-4 cycles (median 4) of anthracycline-based chemotherapy. Changes of mean CA 15-3 values correlated with the UICC response criteria. There was a signifiCAnt fall in mean levels of CA 15-3 after treatment in patients with complete (p < 0.004) and partial regression of metastatic lesions (p < 0.03). Stabilization and progression of the disease were associated with raise in CA 15-3 mean values, but the difference was signifiCAnt only in the latter group (p < 0.02). In 31 out of 39 patients (79.5%) with regressive disease (complete and partial response) CA 15-3 levels decreased by at least 25% after treatment. Nine of 11 (81.8%) patients with stable disease had the Antigen concentrations that did not vary by more than +/- 25% of the initial CA 15-3 value. CA 15-3 levels raised by at least 25% in 22 out of 23 (95.7%) CAses with progressive breast CAncer. Overall, CA 15-3 variations correlated with the disease status in 62 (84.9%) patients. These findings confirmed the usefulness of CA 15-3 determinations in evaluating the effiCAcy of second-line chemotherapy in patients with advanced breast CAncer.
-
129 P - Serum CA 15-3 in node-negative breast CAncer: a marker of prognostic signifiCAnce?
European Journal of Cancer, 1996Co-Authors: J. Wojtacki, A. Dziewulska-bokiniec, G. Rolka-stempniewiczAbstract:Concentrations of CA 15-3 Antigen were measured at diagnosis in the sera of 90 node-negative breast CAncer women. CA 15-3 values correlated with the higher histologiCAl grade (p
J. Wojtacki - One of the best experts on this subject based on the ideXlab platform.
-
Elevation of serum CA 15-3 Antigen: an early indiCAtor of distant metastasis from breast CAncer. Retrospective analysis of 733 CAses
Przeglad lekarski, 2001Co-Authors: J. Wojtacki, G. Rolka-stempniewicz, W J Kruszewski, M Sliwińska, E. Kruszewska, W Hajdukiewicz, Sliwiński W, M Góralczyk, K. Leśniewski-kmakAbstract:UNLABELLED Aim of study was to summarize six-year institutional experience with serial evaluation of circulating CA15-3 Antigen as a method of early detection of breast CAncer relapse. MATERIAL AND METHODS CA15-3 concentrations were assayed immuno-enzymatiCAlly in the sera of 733 women with breast CArcinoma: in 707 CAses marker was analyzed serially (every 4 months during follow-up after completion of radiCAl treatment and when the relapse of breast CAncer was cliniCAlly suspected) and in 26 patients--at diagnosis of locoregional relapse and\or breast CAncer dissemination; 5493 assays of the CA15-3 Antigen were performed in total. The cut-off limit was established at 30 u/ml. Results of CA15-3 tests were analyzed in relation to cliniCAl status of the disease and dominant site of breast CAncer relapse. RESULTS 1) in patients with distant metastases (N = 149), mean serum CA15-3 values and the percentage of positive results were signifiCAntly higher as compared to CAses with locoregional relapse and CArcinoma of the contralateral breast (N = 54; p < 0.0001) and those without cliniCAl evidence of relapse (N = 530; p < 0.0001), in agreement with previous studies; 2) the highest mean values of CA15-3 were observed in patients with liver and multiple metastases, lower in those with bone or lung secondaries, and the lowest when the metastatic involvement of supraclavicular nodes was noticed; 3) the CA15-3 sensitivity rates were higher in patients with liver or bone metastases (91.7% and 91.4%, respectively), as compared to those with multiple (79.5%) and lung (72.4%) secondaries, and the lowest when metastases in supraclavicular nodes (40.0%) or other organs (60.0%) were diagnosed; 4) the comparison of subjects with liver secondaries and those with other sites of breast CAncer dissemination indiCAted statistiCAlly signifiCAnt difference in the mean CA15-3 values (p < 0.0001) and the number of positive results of the test (p < 0.05); 5) the sensitivity rates of CA15-3 Antigen for one, two, three and more skeletal metastases detected by bone scintigraphy were 50%, 100% and 100%, respectively (N = 30); 6) in 84 out of 116 (72.4%) patients with distant metastases, the increased CA15-3 concentration preceded the cliniCAl diagnosis of the relapse with the median lead time 9 months (range: 1-40); 7) the highest positivity rates of the lead time were observed in patients with liver or lung metastases (93.8% and 81.0%, respectively) and the lowest one in those with multiple sites of metastases (43.0%). CONCLUSION The study confirmed the validity of serial CA15-3 assays in the early diagnosis of breast metastatic disease. It is worth to emphasize the high sensitivity of the CA15-3 test in detecting bone metastases (100% in patients with scintigraphiCAlly diagnosed two or more metastatic lesions), but the group of patients was too small to make our observation conclusive. In none of the studies published previously, the beneficial impact of serial CA15-3 assays during follow-up on survival and quality of life in breast CAncer patients was clearly demonstrated. Thus, modifying treatment based solely on increasing marker levels is not recommended.
-
Usefulness of CA 15-3 Antigen determination for evaluation of response to second-line chemotherapy in patients with breast CAncer: preliminary study
Polskie Archiwum Medycyny Wewnetrznej, 1997Co-Authors: J. Wojtacki, A. Dziewulska-bokiniec, G. Rolka-stempniewiczAbstract:The aim of this study was to assess effects of second-line chemotherapy in metastatic breast CAncer via determination of CA 15-3 marker. Analysis included 73 women, in whom distant metastases were diagnosed within 14-72 months (median: 43) after the completion of basic therapy. Average age of patients at primary diagnosis was 50.7 +/- 12.6 years. Dominant sites of metastases were: liver (27 patients) and lungs (24 patients). Serum CA 15-3 was examined immunoenzymatiCAlly at diagnosis of distant metastases and then after 2-4 cycles (median 4) of anthracycline-based chemotherapy. Changes of mean CA 15-3 values correlated with the UICC response criteria. There was a signifiCAnt fall in mean levels of CA 15-3 after treatment in patients with complete (p < 0.004) and partial regression of metastatic lesions (p < 0.03). Stabilization and progression of the disease were associated with raise in CA 15-3 mean values, but the difference was signifiCAnt only in the latter group (p < 0.02). In 31 out of 39 patients (79.5%) with regressive disease (complete and partial response) CA 15-3 levels decreased by at least 25% after treatment. Nine of 11 (81.8%) patients with stable disease had the Antigen concentrations that did not vary by more than +/- 25% of the initial CA 15-3 value. CA 15-3 levels raised by at least 25% in 22 out of 23 (95.7%) CAses with progressive breast CAncer. Overall, CA 15-3 variations correlated with the disease status in 62 (84.9%) patients. These findings confirmed the usefulness of CA 15-3 determinations in evaluating the effiCAcy of second-line chemotherapy in patients with advanced breast CAncer.
-
129 P - Serum CA 15-3 in node-negative breast CAncer: a marker of prognostic signifiCAnce?
European Journal of Cancer, 1996Co-Authors: J. Wojtacki, A. Dziewulska-bokiniec, G. Rolka-stempniewiczAbstract:Concentrations of CA 15-3 Antigen were measured at diagnosis in the sera of 90 node-negative breast CAncer women. CA 15-3 values correlated with the higher histologiCAl grade (p
Umberto Tirelli - One of the best experts on this subject based on the ideXlab platform.
-
CA-15.3 Antigen as predictor of response to EGFR inhibitors in patients with bronchiolo-alveolar CArcinoma
Journal of Clinical Oncology, 2007Co-Authors: Alessandrea Bearz, R. Talamini, Emanuela Vaccher, Michele Spina, Cecilia Simonelli, M. Berretta, Simon Spazzapan, Umberto TirelliAbstract:18151 Background: Bronchiolo-alveolar CArcinoma (BAC) is a subtype of non-small cell lung CAncer (NSCLC). Incidence of pure BAC ranges between 2% and 5% of NSCLC although a BAC histotype may be present in up to 20%. There is no established treatment for BAC, although promising results have been achieved from the use of inhibitors of the Epidermal Growth Factor Receptor (EGFR). It has been demonstrated that there is a very close relationship between responsiveness to EGFR inhibitors Erlotinib and Gefitinib and some factors, including female gender; adenoCArcinoma histotype, with BAC features; Asian origin; and never having smoked. No tumor marker has been validated in the diagnosis and follow-up of lung CAncer. CA 15–3 Antigen serum levels are reported to be pathologiCAlly abnormal in adenoCArcinoma of the lung, although it does not seem to be related to the EGFR pathway. We studied this tumor marker in relation with the treatment with EGFR inhibitors in patients affected by BAC. Methods: We collected data...
-
MUC-1 (CA 15-3 Antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar CArcinoma: an experience on 26 patients.
The International journal of biological markers, 2007Co-Authors: Alessandrea Bearz, R. Talamini, Emanuela Vaccher, Michele Spina, Cecilia Simonelli, Agostino Steffan, M. Berretta, E. Chimienti, Umberto TirelliAbstract:Background Bronchioloalveolar CArcinoma (BAC) is a histologiCAl subtype of non-small cell lung CAncer (NSCLC), particularly of adenoCArcinoma. Given its multifoCAlity and the poor activity of chemotherapy, there is no established treatment for BAC, although promising results have been achieved with inhibitors of the epidermal growth factor receptor (EGFR). No tumor marker has been validated in the diagnosis and follow-up of lung CAncer, in particular to predict the outcome of treatment with EGFR inhibitors. Purpose As CA 15-3 Antigen serum levels are reported to be pathologiCAlly abnormal in adenoCArcinoma of the lung, we chose this tumor marker to monitor treatment with EGFR inhibitors of patients affected by adenoCArcinoma with BAC features or pure BAC. Patients and methods We collected data from 26 consecutive CAuCAsian patients with BAC, mostly women and never smokers, who received EGFR inhibitors. Results We noticed that all patients with normal CA 15-3 serum levels at baseline (15/26, 57.7%) showed a response to EGFR inhibitors, whereas all patients with abnormal CA 15-3 serum levels (11/26, 42.3%) did not. Conclusion Our data suggest that CA 15-3 levels might be a predictive factor for the response to EGFR inhibitors in patients with BAC.
